

World Journal of *Diabetes*

World J Diabetes 2017 July 15; 8(7): 311-389



**EDITORIAL**

- 311 PCSK9 and carbohydrate metabolism: A double-edged sword
Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS

REVIEW

- 317 Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia
Mbata O, Abo El-Magd NF, El-Remessy AB

MINIREVIEWS

- 330 PTPN22 and islet-specific autoimmunity: What have the mouse models taught us?
Galvani G, Fousteri G
- 337 Saponins as adipokines modulator: A possible therapeutic intervention for type 2 diabetes
Elekofehinti OO, Ejelonu OC, Kamdem JP, Akinlosotu OB, Adanlawo IG

ORIGINAL ARTICLE**Retrospective Cohort Study**

- 346 Vitamin D levels in subjects with or without chronic kidney disease among Veterans with diabetes in North East United States
Yaturu S, Youngberg B, Zdunek S

Observational Study

- 351 Type 2 diabetes in a Senegalese rural area
Duboz P, Boëtsch G, Gueye L, Macia E
- 358 Quality of sleep and its determinants among people with type 2 diabetes mellitus in Northwest of Iran
Shamshirgaran SM, Ataei J, Malek A, Iranparvar-Alamdari M, Aminisani N

Prospective Study

- 365 Are body mass index and waist circumference significant predictors of diabetes and prediabetes risk: Results from a population based cohort study
Haghighatdoost F, Amini M, Feizi A, Iraj B
- 374 Effect of bariatric surgery on adiposity and metabolic profiles: A prospective cohort study in Middle-Eastern patients
Mazidi M, Rezaie P, Jangjoo A, Tavassoli A, Rajabi MT, Kengne AP, Nematy M

Randomized Controlled Trial

- 381** Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods

Sood V, Bhansali A, Mittal BR, Singh B, Marwaha N, Jain A, Khandelwal N

Contents

World Journal of Diabetes
Volume 8 Number 7 July 15, 2017

ABOUT COVER

Editorial Board Member of *World Journal of Diabetes*, Wei-Chung V Yang, PhD, Director, Professor, Center for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan

AIM AND SCOPE

World Journal of Diabetes (*World J Diabetes*, *WJD*, online ISSN 1948-9358, DOI: 10.4239), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJD covers topics concerning α , β , δ and PP cells of the pancreatic islet, the effect of insulin and insulinresistance, pancreatic islet transplantation, adipose cells and obesity.

We encourage authors to submit their manuscripts to *WJD*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Diabetes is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, and Scopus.

FLYLEAF

I-VI Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fung-Fung Ji*
Proofing Editorial Office Director: *Jin-Lai Wang*

NAME OF JOURNAL

World Journal of Diabetes

ISSN

ISSN 1948-9358 (online)

LAUNCH DATE

June 15, 2010

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Lu Qi, MD, PhD, Assistant Professor, Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, United States

Jingbo Zhao, PhD, Associate Professor, Aalborg Hospital Science and Innovation Centre, Aalborg Hospital, Aarhus University Hospital, Aalborg 9000, Denmark

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1948-9358/editorialboard.htm>

EDITORIAL OFFICE

Xiu-Xia Song, Director
World Journal of Diabetes
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE

July 15, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<http://www.f6publishing.com>

Saponins as adipokines modulator: A possible therapeutic intervention for type 2 diabetes

Olusola Olalekan Elekofehinti, Oluwamodupe Cecilia Ejelonu, Jean Paul Kamdem, Oluwaseun Benedicta Akinlosotu, Isaac Gbadura Adanlawo

Olusola Olalekan Elekofehinti, Department of Biochemistry, University of Ado-Ekiti, Ado-Ekiti 360221, Ekiti State, Nigeria

Oluwamodupe Cecilia Ejelonu, Oluwaseun Benedicta Akinlosotu, Department of Biochemistry, Adekunle Ajasin University, Akungba Akoko 342111, Ondo State, Nigeria

Jean Paul Kamdem, Departamento de Ciências Biológicas, Universidade Regional do Cariri - URCA, Campus Pimenta, Crato, Ceará 63100-000, Brazil

Isaac Gbadura Adanlawo, Department of Biochemistry, Federal University of Technology, Akure 340252, Ondo State, Nigeria

Author contributions: All authors contributed to this manuscript.

Conflict-of-interest statement: The authors declare no conflict of interest with respect to the research, authorship, and/or publication of this article.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Dr. Olusola Olalekan Elekofehinti, Department of Biochemistry, University of Ado-Ekiti, University Avenue, Akure Ilesha-Akure Expressway, PMB 704, Akure 340252, Ondo State, Nigeria. sola_eleko@yahoo.com
Telephone: +234-803-4450611

Received: January 7, 2017

Peer-review started: January 11, 2017

First decision: February 17, 2017

Revised: March 13, 2017

Accepted: April 6, 2017

Article in press: April 10, 2017

Published online: July 15, 2017

Abstract

Development of type 2 diabetes has been linked to β -cell failure coupled with insulin resistance and obesity. Adipose tissue, known as the fat store, secretes a number of hormones and proteins collectively termed adipokines some of which regulate insulin sensitivity. Dysregulation in the secretion of adipokines has been linked to insulin resistance and type 2 diabetes. In this review, we summarized evidence of the role of adipokines with focus on leptin, adiponectin, adipisin, visfatin and apelin in the pathogenesis of type 2 diabetes and discussed the potential of saponins to modify the ill-regulated adipokines secretions, which could promote the use of this class of phytochemicals as potential antidiabetic agents.

Key words: Adipokines; Adipose tissue; Insulin resistance; Antidiabetic; Obesity

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: β -cell dysfunction and insulin resistance are linked to type 2 diabetes. Adipokines produced from adipose tissues regulate glucose homeostasis and insulin sensitivity. Dysregulation of adipokines are linked to insulin resistance and disruption of glucose Homeostasis. Saponins modulate the activity of some adipokines hence may serve as therapy for treatment of type 2 diabetes.

Elekofehinti OO, Ejelonu OC, Kamdem JP, Akinlosotu OB, Adanlawo IG. Saponins as adipokines modulator: A possible therapeutic intervention for type 2 diabetes. *World J Diabetes*

INTRODUCTION

The Adipose tissue is the major origin of fatty acids in the postprandial fasting state for energy use and heat production^[1]. Its accumulation, particularly the white adipose tissue (WAT), has been reported to be the factor responsible for obesity, which has been associated to type 2 diabetes and cardiovascular disease^[2]. The statistic of individuals suffering from type 2 diabetes is growing worldwide and based on data from International Diabetes Federation, about 415 million people are affected by this metabolic but deadly disease, contributing to an explosion in type 2 diabetes linked health problems. Due to high rate of morbidity and mortality, type 2 diabetes is considered one of the major public health problem in many parts of the world^[3].

Nowadays, adipose tissue is known to serve as endocrine organ that secrete pro- and anti-inflammatory mediators including adipokines, which are cell-signaling proteins that function as hormones^[4]. Of particular importance is the ability of adipokines to function as classic circulating hormone that communicate with adipose tissue itself as well as other organs like muscle, liver, brain and the immune system^[5]. It should be stressed that these adipokines are secreted to modulate inflammation and insulin resistance.

Insulin resistance is key to evolution of type 2 diabetes mellitus, which is regarded epidemic and culminating in high cardiovascular disease risk and death rate. Therefore, an in-depth knowledge of mechanisms implicit in insulin resistance is needful to fight the widespread occurrence of type 2 diabetes and their associated diseases^[3]. Obesity's contribution to type 2 diabetes has been linked to dysregulation of adipokines (*i.e.*, improper production of adipokines by adipose tissue) and glucose uptake^[6].

Increasing data have opened our understanding on adipose tissue over the past few decades giving us a clear picture about adipose tissue not only being an inert excess fat storage depot but also a dynamic endocrine organ secreting a wide range of bioactive protein secretions^[7,8]. As mentioned earlier, adipokines or adipocytokines are peptides or cytokines that are secreted by adipose tissue. The adipokines list increases yearly, as both novel and existing adipokines secreted by adipose tissue are reported from time to time^[8]. Adipokines play a substantial role in the maintenance of adipogenesis, chemo attraction of immune cells into adipose tissue, adipocyte function *via* autocrine/paracrine signaling, regulating appetite, energy expenditure and spontaneous activity, insulin sensitivity and energy metabolism in the brain and




Figure 1 Peptides and cytokines secretion (adipokines) of the adipose tissue. TNF: Tumor necrotic factor; IL: Interleukin.

peripheral target tissues^[9,10]. Some of the biologically active protein secretion of the adipocytes includes adiponectin, adipsin, leptin, resistin, apelin, retinol binding protein 4 (RBP4), vaspin, hepcidin and visfatin while the cytokine secretions are tumor necrotic factor- α , interleukin-6 and monocyte chemoattractant protein-1^[11] (Figure 1).

In the past few years, particular attention has been paid to finding natural products and/or plants derived chemicals with the potential to improve obesity (by suppressing appetite, retarding body fat accumulation and improving weight loss) and glucose uptake by modifying adipokines^[12-15]. Saponins are steroid or triterpenoids glycosides found in many plants and plant products. They exhibit a variety of pharmacology activities including antidiabetic, hypocholesterolaemic, anticarcinogenic, and hypoglycaemia among others^[16-18]. In this review, our focus shall be on the mechanisms linking adipokines to type 2 diabetes and discuss the ability of saponins to modulate adipokines thereby improving insulin sensitivity.

ADIPOKINES IN INSULIN RESISTANCE

A substantial risk factor for type 2 diabetes is obesity because it has been connected to insulin resistance. The diminished potential of tissues to react to insulin activity is referred to as insulin resistance. Adipose tissue is one of the tissues that respond to insulin action by storing triglycerides through some mechanisms which include enhancement of differentiation of pre-adipocytes to adipocytes, enhancing the intake of glucose and fatty acids derived from circulating lipoproteins and




Figure 2 Insulin signaling leading to increase in adipocyte glucose uptake. PI3K: Phosphatidylinositol 3-kinase; Akt: Protein kinase B; MAPK: Mitogen activated protein kinase; Glut 4: Glucose transporter 4; Raf: Raf family of serine/threonine kinases; Ras: Superfamily of small GTPases; MEK: MAPK kinase; IRS-1: Insulin receptor substrate 1.

lipogenesis in mature adipocytes, and inhibiting lipid breakdown (lipolysis)^[19]. Initiation of insulin signaling starts by binding of insulin to its receptor located on the cell membrane. The binding leads to activation of insulin receptor substrate (IRS) proteins by phosphorylation thereby activating two main associated signaling pathways: Namely the phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway and the Ras-mitogen-activated protein kinase (MAPK) pathway. The most important pathway for most metabolic actions of insulin is PI3K-AKT/PKB. The phosphorylated IRS-1, by the insulin receptor, triggers PI3K by binding to its SH2 domain. PI3K produces phosphatidylinositol-(3,4,5)-triphosphate (PIP3), which is a lipid second messenger that triggers many phosphatidylinositol-(3,4,5)-triphosphate-dependent serine/threonine kinases, including AKT/PKB. These downstream signaling pathways of insulin result in the mobilization of glucose transporter 4 (Glut 4) to the plasma membrane from the cytosol, resulting in increased adipocyte glucose uptake (Figure 2). The MAPK pathway that is the second pathway associated with IRS-1 phosphorylation is not associated metabolic actions of insulin. It is rather involved in inducing mitogenic and growth effects of insulin. Insulin also has anti-lipolytic effect in adipose tissue, through PI3K activation which stimulates phosphodiesterase-3 causing hydrolysis of more adenosine 3',5'-cyclic monophosphate in adipocytes, thereby limit the mobilization of fatty acids from adipose tissue^[19].

One of the mechanisms to explain the high risk of

type 2 diabetes with obesity is as a result of defect in blood level of adipokines on metabolic tissues^[20]. Study has suggested a probable role of adipocytes in the progression of insulin resistance. Adipose tissue releases free fatty acids (FFAs) and various adipokines that have been implicated in unnatural insulin signaling. Study has demonstrated that the enlargement of adipose tissue depots leads to obesity causing dysregulation in adipokine secretion, typifying the potential pathophysiological link between adipose tissue secretions (adipokines), obesity and type 2 diabetes^[21]. Compositional changes in obese state lead to dysregulation in secretion of adipocyte-secreted hormones (adipokines). Adipose tissue secretes many adipokines like RBP4, leptin, resistin, vaspin, visfatin, hepcidin, adiponectin and inflammatory cytokines which regulate insulin sensitivity, immune response, cardiovascular function, and many physiological processes^[22]. A strong correlation exists with level of circulating adipokines and signaling pathways modulated by insulin (such as JAK2/STAT3, MAPK, PI3K and AMPK pathways), suggesting a link between adipokines and insulin action.

Adipokines such as adiponectin and leptin, visfatin, apelin are now known to modify insulin sensitivity and/or secretion which are the two major events that occur in the evolvement of type 2 diabetes. For the purpose of this review, we will focus our attention on leptin, adiponectin, adipin visfatin and apelin. Particularly, we will discuss their mechanism of action in regard

to insulin resistance and the potential of saponins to modulate peptides adipokines.

Leptin and insulin sensitivity

Leptin is an endogenous sensing factor that provides a critical link between the environment, metabolism, and immune function^[22]. It plays vital role in the metabolic regulation of satiety, appetite, food intake, activity and energy expenditure. The relationship of leptin with insulin resistance, obesity and cardiovascular disease has been extensively studied since its discovery in 1994. As mentioned earlier, obesity, which is considered a major public health problem, is often linked with type 2 diabetes mellitus, cardiovascular diseases as well as cancer. These diseases have been linked to a lowered reactivity for leptin, an adipocyte hormone that is principally secreted by the WAT to targets specific receptors in the arcuate nucleus of the hypothalamus in order to regulate food intake and energy expenditure. Leptin was originally thought to act only as a satiety factor but the presence of OB-R leptin receptors in almost all tissues suggest the pleiotropism of leptin in all tissues expressing leptin receptors. The actions of leptin are mediated *via* actions on leptin receptors (LepRs) generally expressed by neurons in the central nervous system (CNS)^[23]. Leptin receptors (OB-R) activation stimulates several intracellular signaling pathways implicated in insulin sensitivity such as the PI3K, JAK2/STAT3, MAPK, and AMPK pathways, IRSs^[24] for review see^[25,26].

Saponin's effect on leptin: Saponins have been implicated in regulation of energy metabolism through activation of AMPK^[27,28]. In addition, most of the signaling pathways (JAK2/STAT3, MAPK, PI3K and AMPK) being modulated by leptin are also modulated by saponins^[29-31]. Several studies on the effect of saponins on leptin have been documented^[32]. While some recorded increase in serum leptin concentration with saponin administration^[31,33], others documented decrease in serum leptin concentration following saponin administration^[34,35].

In a study, Yang *et al.*^[35] reported that *Panax notoginseng* saponins demonstrated anti-hyperglycemic and anti-obese activities as a result of improved insulin and leptin sensitivity. Tea saponin treatment was shown to reduce the protein levels of pro-inflammatory cytokines [tumor necrosis factor α (TNF α), interleukin-6 (IL-6), and/or IL-1 β] and nuclear factor- κ B signaling (phosphorylated inhibitory- κ B kinase and phosphorylated inhibitory- κ B α) in adipose tissue and the liver^[36]. The anti-inflammatory effect of tea saponin was associated with improved glycemic status in the treated animals, which was evidenced by improved glucose tolerance, homeostasis model assessment, and fasting plasma insulin. In the hypothalamus, tea saponin decreased both pro-inflammatory cytokines and inflammatory signaling in the mediobasal hypo-

thalamus. Tea saponin treatment also enhanced the anorexigenic effect of central leptin administration, restored leptin phosphorylated signal transducer and activator of transcription-3 (p-STAT3) signaling in the arcuate nucleus, making tea saponin an anti-obesity and anti-diabetic agent. Other plants whose saponins effects have been probed on leptin are *Yucca schidigera*^[32]. Based on the aforementioned information, saponins appear to be an activator of AMP-activated protein kinase (AMPK), which is a key regulator of energy balance and fat metabolism and PI3K signaling, leading to improve insulin sensitivity. Hence, saponin may be a potential anti-obesity agent by reducing insulin resistance and improving insulin sensitivity.

Adiponectin and insulin sensitivity

Adiponectin is a protein hormone (adipocyte hormone) modulating a number of metabolic processes such as fatty acid oxidation and glucose regulation^[27,37]. It plays a crucial role in the evolution of insulin resistance and atherosclerosis. The concentration of circulating adiponectin is high in normal subject but lower in obese subjects than in lean subjects. Adiponectin is negatively correlated with adiposity. Its level is also reduced in insulin resistance and type 2 diabetes. A reduction in adiponectin level occurs prior to the onset of type 2 diabetes and oral administration of adiponectin is generally followed by decrease blood glucose levels which culminates in increased insulin sensitivity (for reviews, see^[38,39]). Data from animal studies have linked decrease expression of adiponectin to some degree of insulin resistance thereby linking hypo adiponectinaemia to insulin resistance. Increase fatty acid oxidation and hepatic glucose production inhibition have been put forward as mechanism of enhancement of insulin sensitivity by adiponectin^[40]. AdipoR1 and AdipoR2 are characterized adiponectin receptors and they contain 7 transmembrane domains, with different structure and function. Both AdipoR1 and AdipoR2 are predominant in the skeletal muscle while AdipoR2 is primarily expressed by liver^[41]. AdipoR1 and AdipoR2 mediate the antidiabetic metabolic effect of adiponectin, and their expression are repressed in obesity-linked insulin resistance^[38,39].

Saponin's effect on adiponectin: Accumulating evidences from the literature indicate that saponin treatment increases adiponectin level, and this effect might play an important role in enhancement of insulin sensitivity by saponins^[17,27,42]. Duan *et al.*^[43] reported that chikusetsu saponin increased adiponectin level and enhanced neuronal AdipoR1 as well as downstream molecules of adiponectin including AMPK, and glycogen synthase kinase 3 beta (GSK-3 β) expression, in a concentration-dependent manner in diabetic mice. Platyconic acid is a saponin from *Platycodi radix* that potentiated the expression of adiponectin in adipose tissue leading to improved insulin signaling^[42]. Likewise,




Figure 3 Adipsin and insulin secretion in beta cell. Adipsin potentiates insulin secretion through cleavage of CFB to form C3 that is hydrolyzed to form C3a. C3a activates C3AR1, which acts on B-cells of the pancreas to secrete insulin. CFB: Complement factor B.

saponins from *Helicteres isora* increased the expression of adiponectin^[17]. Other saponins which exhibited increased expression of adiponectin include saponins isolated from *Astragalus membranaceus*^[44] and *Ilex paraguariensis*^[45].

Adipsin and insulin sensitivity

Adipsin was the first adipokine described^[46] and is one of the major proteins of adipose cells that inversely correlate with many animal models of obesity and diabetes^[46]. Later this adipokine identified to be complement factor D^[47-49], which catalyzes the rate-limiting step of the alternative pathway of complement activation^[50]. Since then, adipsin has been shown to play pivotal roles in models of ischemia reperfusion and sepsis^[51-53].

Adipsin stimulates glucose transport enhancing triglyceride accumulation in fats cells and also inhibits lipolysis^[54]. The adipsin-acylation stimulating protein

(ASP) system is involved in the regulation of triglyceride metabolism in adipocytes. This system increases triglyceride synthesis rate in adipocytes by translocation of glucose transporters from intracellular vesicles to the plasma membrane, enhancing specific membrane glucose transport^[27,55].

Recently, the relationship between the immune system and adipose tissue has linked complement biology to pathogenesis of type 2 diabetes. This can be explained at least in part to the fact that certain proteins of the complement pathway such as adipsin are preferentially expressed in the adipose tissue and are dis-regulated in models of obesity and diabetes^[53]. Adipsin was recently identified as one of the most abundant and specifically expressed adipose proteins that links fat cells and obesity to Beta cell function^[53]. It can increase insulin secretion by producing the peptide complement 3a (C3a).

Adipsin splits complement factor B in the alternative complement pathway, hence catalyzing the formation of C3 convertase, contributing to a hydrolysis cascade that produces various complement fragments including complement 3a (C3a), C3b, C5a and C5b^[48]. C3a potentiates insulin secretion by interacting with C3AR1 to act on Beta cells (Figure 3) only during hyperglycemia and does not induce Beta cells to release insulin at low glucose level^[56].

Saponin's effect on adipsin: Bhavsar *et al.*^[17] reported that saponins from *Helicteres isora* significantly increase the expression of adipsin when compared with control db/db mice. Zhang *et al.*^[57] also established the link between *Panax notoginseng* saponins and complement factor 3 (C3). The ability of saponin to stimulate adipsin and C3 brings to light the beneficial role of saponins in improving insulin sensitivity and hyperglycemia.

Visfatin and insulin sensitivity

Visfatin also known as nicotinamide phosphoribosyl-transferase (NAMPT), or pre-B-cell colony-enhancing factor 1 (PBEF-1) is an adipokine mainly synthesized and secreted in visceral fat (WAT) hence its name "visfatin"^[58]. It is produced as a result of adipocyte differentiation and its potential to lower blood glucose is as a result of its nicotinamide phosphoribosyl transferase activity^[59]. Visfatin possess insulin mimetic effects through enhancement of glucose uptake by myocytes and adipocytes and suppression of hepatocyte glucose production/release^[11,60]. Visfatin also exert its effect on insulin transduction pathway through induction of tyrosine phosphorylation of insulin receptors 1 and 2, activation of phosphatidylinositol-3 kinase (PI3K), protein kinase B (AKT) and MAPK. Visfatin has the same affinity as insulin for insulin receptor but its binding to insulin receptor occur at a different site. Brown *et al.*^[61] demonstrated that visfatin is able to regulate insulin secretion and insulin receptor signaling in beta-cells of the pancreas. More recently, Gouranton *et al.*^[62]




Figure 4 Modulation of adipokines (peptides) by saponin.

Saponin increases the expression of leptin, adiponectin, adipsin, visfatin but reduces the expression of apelin. PI3K: Phosphatidylinositol 3-kinase; AKT: Protein kinase B; MAPK: Mitogen activated protein kinase; AMPK: 5'AMP-activated protein kinase; STAT3: Signal transducer and activator of transcription 3; JAK2: Janus kinase 2.

demonstrated that visfatin is involved in TNF α -mediated insulin resistance through NDA⁺/Sirt1/PTP1B pathway in 3T3-L3 adipocytes.

Saponin's effect on visfatin: Increasing evidence has shown that saponins act the same way as visfatin by activating PI3K, protein kinase B (AKT) and MAPK suggesting that saponins can regulate insulin transduction pathway^[17,27,63]. Macrostemonoside A, a steroidal saponins from *Allium* genus increased the synthesis as well as release of visfatin in 3T3-L1 adipocytes and elevated mRNA levels of this adipokine in a dose- and time-dependent mode^[64,65].

Apelin and insulin sensitivity

Apelin, a 36 amino-acid peptide has been characterized in a variety of tissues, such as CNS with high expression in the hypothalamus, stomach, heart, skeletal muscle, and WAT. It is an endogenous ligand of the G-protein-coupled receptor (APJ)^[65,66]. The G protein-coupled receptor APJ and its connected ligand, apelin, are widely expressed all through human body. They are linked to different key physiological processes including cardiovascular functions, fluid homeostasis, angiogenesis and energy metabolism regulation. The serum level of apelin is directly proportional to insulin resistance^[67-69] and liver cirrhosis. Inflammation and oxidative stress have been shown increase plasma level of apelin.

One of the first observed effect of apelin linked to glucose metabolism, aside that of insulin secretion is its ability to lower glucose level in fasted states and during *in-vivo* mice model of glucose tolerance test. This effect is mainly due to enhanced glucose uptake in target tissues such as adipose tissue and skeletal muscle^[70,71].

Data from *in vivo* study revealed that reduced expression of apelin in adipocyte and lower serum concentration might contribute to enhanced insulin sensitivity that is significantly independent of weight loss through an unknown mechanism.

In vitro experiment using C2C12 muscle cells showed that apelin enhanced glucose transport through AMPK pathway. Also apelin increased muscle Akt

phosphorylation in both *ex vivo* and *in vitro* studies^[70,72]. Interestingly, apelin triggers glucose uptake in muscle of obese as well as insulin-resistant mice ultimately leading to enhanced insulin sensitivity^[70,71].

Saponin's effect on apelin: Only one study reported the potential beneficial effect of saponin on apelin. Xiu-Juan *et al*^[73] demonstrated that-saponins from *Astragalus membranaceus* decrease the expression of Apelin/APJ mRNA in the high glucose group when compared to control.

MODULATION OF ADIPOKINES (PEPTIDES) BY SAPONIN

We have demonstrated in this review that saponin modulates leptin, adiponectin, adipsin, visfatin and apelin (Figure 4). Leptin and visfatin activation by saponin may be the link between saponin and insulin signaling. Earlier studies have documented the potential of saponin to activate PI3K and AKT^[17], the activation of PI3K and AKT by saponin may be the downstream signaling resulting from leptin and visfatin activation.

Primarily, hyperlipidemia, serum triglycerides and FFA are elevated in type 1 and type 2 diabetes but plasma FFA are elevated in obese subjects. An elevated plasma level of FFA has been linked to increase insulin resistance in muscle and liver. One of the therapeutic approaches for type 2 diabetes has been to lower circulating level of FFA^[74]. Activation of adiponectin by saponin could increase fatty acid oxidation and inhibit hepatic glucose production thereby lowering plasma FFA levels. Increase expression of adiponectin by saponin could be one of the mechanisms of improving insulin sensitivity by saponin. Increase expression of adipsin by saponin (Figure 4) is also another way by which saponin can improve insulin sensitivity in type 2 diabetes.

CONCLUSION

This mini review has outlined the link between adipokines, insulin resistance and type 2 diabetes and

the ability of saponin to modulate peptide adipokines (leptin, adiponectin, adipsin, visfatin and apelin) leading to improved insulin sensitivity. Further insight into this area of developing saponin into a class of antidiabetic drug will be invaluable and of tremendous impact on the treatment and the early intervention and prevention of diabetes.

REFERENCES

- Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. *Cell* 2007; **131**: 242-256 [PMID: 17956727 DOI: 10.1016/j.cell.2007.10.004]
- Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *JAMA* 1999; **282**: 1523-1529 [PMID: 10546691 DOI: 10.1001/jama.282.16.1523]
- Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. *Genes Dev* 2007; **21**: 1443-1455 [PMID: 17575046 DOI: 10.1101/gad.1550907]
- Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 2011; **11**: 85-97 [PMID: 21252989 DOI: 10.1038/nri2921]
- Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. *Front Endocrinol (Lausanne)* 2013; **4**: 71 [PMID: 23781214 DOI: 10.3389/fendo.2013.00071]
- Ahn YM, Kim SK, Kang JS, Lee BC. Platycodon grandiflorum modifies adipokines and the glucose uptake in high-fat diet in mice and L6 muscle cells. *J Pharm Pharmacol* 2012; **64**: 697-704 [PMID: 22471365 DOI: 10.1111/j.2042-7158.2012.01455.x]
- Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. *Ann N Y Acad Sci* 2010; **1212**: E1-E19 [PMID: 21276002 DOI: 10.1111/j.1749-6632.2010.05875.x]
- Dunmore SJ, Brown JE. The role of adipokines in β -cell failure of type 2 diabetes. *J Endocrinol* 2013; **216**: T37-T45 [PMID: 22991412 DOI: 10.1530/JOE-12-0278]
- Blüher M. Adipose tissue dysfunction in obesity. *Exp Clin Endocrinol Diabetes* 2009; **117**: 241-250 [PMID: 19358089 DOI: 10.1055/s-0029-1192044]
- Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. *Metabolism* 2015; **64**: 131-145 [PMID: 25497344]
- Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. *Diabetes Metab* 2008; **34**: 2-11 [PMID: 18093861 DOI: 10.1016/j.diabet.2007.09.004]
- Kim MJ, Kim HK. Perilla leaf extract ameliorates obesity and dyslipidemia induced by high-fat diet. *Phytother Res* 2009; **23**: 1685-1690 [PMID: 19444921 DOI: 10.1002/ptr.2811]
- Konopko-Zubrzycka M, Baniukiewicz A, Wróblewski E, Kowalska I, Zarzycki W, Górski M, Dabrowski A. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. *J Clin Endocrinol Metab* 2009; **94**: 1644-1649 [PMID: 19258408 DOI: 10.1210/jc.2008-1083]
- Nammi S, Sreemantula S, Roufogalis BD. Protective effects of ethanolic extract of Zingiber officinale rhizome on the development of metabolic syndrome in high-fat diet-fed rats. *Basic Clin Pharmacol Toxicol* 2009; **104**: 366-373 [PMID: 19413656 DOI: 10.1111/j.1742-7843.2008.00362.x]
- Stenblom EL, Weström B, Linnings C, Bonn P, Farrell M, Rehfeld JF, Montelius C. Dietary green-plant thylakoids decrease gastric emptying and gut transit, promote changes in the gut microbial flora, but does not cause steatorrhea. *Nutr Metab (Lond)* 2016; **13**: 67 [PMID: 27777602 DOI: 10.1186/s12986-016-0128-4]
- Elekofehinti OO. Saponins: Anti-diabetic principles from medicinal plants - A review. *Pathophysiology* 2015; **22**: 95-103 [PMID: 25753168 DOI: 10.1016/j.pathophys.2015.02.001]
- Bhavsar SK, Singh S, Giri S, Jain MR, Santani DD. Effect of saponins from *Helicteres isora* on lipid and glucose metabolism regulating genes expression. *J Ethnopharmacol* 2009; **124**: 426-433 [PMID: 19505560 DOI: 10.1016/j.jep.2009.05.041]
- Francis G, Kerem Z, Makkar HP, Becker K. The biological action of saponins in animal systems: a review. *Br J Nutr* 2002; **88**: 587-605 [PMID: 12493081 DOI: 10.1079/BJN2002725]
- Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. *Int J Mol Sci* 2014; **15**: 6184-6223 [PMID: 24733068 DOI: 10.3390/ijms15046184]
- Brown JE. Dysregulated adipokines in the pathogenesis of type 2 diabetes and vascular disease. *Current Topics* 2012; **12**: 249-254 [DOI: 10.1177/1474651412464794]
- Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005; **115**: 1111-1119 [PMID: 15864338 DOI: 10.1172/JCI25102]
- Andrade-Oliveira V, Câmara NO, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. *J Diabetes Res* 2015; **2015**: 681612 [PMID: 25918733 DOI: 10.1155/2015/681612]
- Coppari R, Bjørbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. *Nat Rev Drug Discov* 2012; **11**: 692-708 [PMID: 22935803 DOI: 10.1038/nrd3757]
- Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular consequences. *Circ Res* 2007; **101**: 545-559 [PMID: 17872473 DOI: 10.1161/CIRCRESAHA.107.156596]
- Frühbeck G. Intracellular signalling pathways activated by leptin. *Biochem J* 2006; **393**: 7-20 [PMID: 16336196 DOI: 10.1042/BJ20051578]
- Donato J, Frazão R, Elias CF. The PI3K signaling pathway mediates the biological effects of leptin. *Arq Bras Endocrinol Metabol* 2010; **54**: 591-602 [PMID: 21085763 DOI: 10.1590/S0004-27302010000700002]
- Elekofehinti OO, Omotuyi IO, Kamdem JP, Ejelonu OC, Alves GV, Adanlawo IG, Rocha JB. Saponin as regulator of biofuel: implication for ethnobotanical management of diabetes. *J Physiol Biochem* 2014; **70**: 555-567 [PMID: 24563096 DOI: 10.1007/s13105-014-0325-4]
- Ge YQ, Xu XF, Yang B, Chen Z, Cheng RB. Saponins from *Rubus parvifolius* L. induce apoptosis in human chronic myeloid leukemia cells through AMPK activation and STAT3 inhibition. *Asian Pac J Cancer Prev* 2014; **15**: 5455-5461 [PMID: 25041018 DOI: 10.7314/APJCP.2014.15.13.5455]
- Uzayisenga R, Ayeka PA, Wang Y. Anti-diabetic potential of Panax notoginseng saponins (PNS): a review. *Phytother Res* 2014; **28**: 510-516 [PMID: 23846979 DOI: 10.1002/ptr.5026]
- Hu X, Wang S, Xu J, Wang DB, Chen Y, Yang GZ. Triterpenoid saponins from *Stauntonia chinensis* ameliorate insulin resistance via the AMP-activated protein kinase and IR/IRS-1/PI3K/Akt pathways in insulin-resistant HepG2 cells. *Int J Mol Sci* 2014; **15**: 10446-10458 [PMID: 24918297 DOI: 10.3390/ijms150610446]
- Kim H, Hwang J, Kim MJ, Yang H, Sung M, Kim S, Park S, Gu E, Park Y, Kwon D. The inhibitory effect of saponin derived from Cheonggukjang on adipocyte differentiation In vitro. *Food Sci Biotechnol* 2014; **23**: 1273 [DOI: 10.1007/s10068-014-0175-4]
- Kucukkurt I, Dunder Y. Effects of dietary Yucca schidigera supplementation on plasma leptin, insulin, iodated thyroid hormones and some biochemical parameters in rat. *Revue Méd Vét* 2013; **164**: 362-367
- Kucukkurt I, Akkol EK, Karabag F, Ince S, Sutar I, Eryavuz A, Sozibilir. Determination of the regulatory properties of Yucca schidigera extracts on the biochemical parameters and plasma hormone levels associated with obesity. *Rev Bras Farmacogn* 2015; **26**: 246-250 [DOI: 10.1016/j.bjp.2015.12.005]
- Kim JH, Hahm DH, Yang DC, Kim JH, Lee HJ, Shim I. Effect of crude saponin of Korean red ginseng on high-fat diet-induced obesity in the rat. *J Pharmacol Sci* 2005; **97**: 124-131 [PMID: 15655288 DOI: 10.1254/jphs.FP0040184]
- Yang CY, Wang J, Zhao Y, Shen L, Jiang X, Xie ZG, Liang N, Zhang L, Chen ZH. Anti-diabetic effects of Panax notoginseng saponins and its major anti-hyperglycemic components. *J Ethnopharmacol* 2010; **130**: 231-236 [PMID: 20435129 DOI: 10.1016/j.jep.2010.04.039]

- 36 **Yu Y**, Wu Y, Szabo A, Wu Z, Wang H, Li D, Huang XF. Teasaponin reduces inflammation and central leptin resistance in diet-induced obese male mice. *Endocrinology* 2013; **154**: 3130-3140 [PMID: 23751875 DOI: 10.1210/en.2013-1218]
- 37 **Al-Braich MS**, Al-Husaini NK, Saleh SH, Awn MF. Effect of adiponectin level in type II diabetic postmenopausal women compared to healthy women. *Eur J Med* 2014; **3**: 4-7 [DOI: 10.13187/ejm.2014.1.4]
- 38 **Yadav A**, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. *Clin Chim Acta* 2013; **417**: 80-84 [PMID: 23266767 DOI: 10.1016/j.cca.2012.12.007]
- 39 **Kadowaki T**, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *J Clin Invest* 2006; **116**: 1784-1792 [PMID: 16823476 DOI: 10.1172/JCI29126]
- 40 **Lihn AS**, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. *Obes Rev* 2005; **6**: 13-21 [PMID: 15655035 DOI: 10.1111/j.1467-789X.2005.00159.x]
- 41 **Coelho M**, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. *Arch Med Sci* 2013; **9**: 191-200 [PMID: 23671428 DOI: 10.5114/aoms.2013.33181]
- 42 **Kwon DY**, Kim YS, Ryu SY, Choi YH, Cha MR, Yang HJ, Park S. Platycodon acid, a saponin from *Platycodon radix*, improves glucose homeostasis by enhancing insulin sensitivity in vitro and in vivo. *Eur J Nutr* 2012; **51**: 529-540 [PMID: 21847688 DOI: 10.1007/s00394-011-0236-x]
- 43 **Duan J**, Yin Y, Cui J, Yan J, Zhu Y, Guan Y, Wei G, Weng Y, Wu X, Guo C, Wang Y, Xi M, Wen A. Chikusetsu Saponin IVa Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice via Adiponectin-Mediated AMPK/GSK-3 β Pathway In Vivo and In Vitro. *Mol Neurobiol* 2016; **53**: 728-743 [PMID: 25636683 DOI: 10.1007/s12035-014-9033-x]
- 44 **Agyemang K**, Han L, Liu E, Zhang Y, Wang T, Gao X. Recent Advances in Astragalus membranaceus Anti-Diabetic Research: Pharmacological Effects of Its Phytochemical Constituents. *Evid Based Complement Alternat Med* 2013; **2013**: 654643 [PMID: 24348714 DOI: 10.1155/2013/654643]
- 45 **Arçari DP**, Bartchewsky W, dos Santos TW, Oliveira KA, Funck A, Pedrazzoli J, de Souza MF, Saad MJ, Bastos DH, Gambero A, Carvalho Pde O, Ribeiro ML. Antiobesity effects of yerba maté extract (*Ilex paraguariensis*) in high-fat diet-induced obese mice. *Obesity* (Silver Spring) 2009; **17**: 2127-2133 [PMID: 19444227 DOI: 10.1038/oby.2009.158]
- 46 **Cook KS**, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, Spiegelman BM. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. *Science* 1987; **237**: 402-405 [PMID: 3299705 DOI: 10.1126/science.3299705]
- 47 **Flier JS**, Cook KS, Usher P, Spiegelman BM. Severely impaired adipin expression in genetic and acquired obesity. *Science* 1987; **237**: 405-408 [PMID: 3299706 DOI: 10.1126/science.3299706]
- 48 **Rosen BS**, Cook KS, Yaglom J, Groves DL, Volanakis JE, Damm D, White T, Spiegelman BM. Adipsin and complement factor D activity: an immune-related defect in obesity. *Science* 1989; **244**: 1483-1487 [PMID: 2734615 DOI: 10.1126/science.2734615]
- 49 **White RT**, Damm D, Hancock N, Rosen BS, Lowell BB, Usher P, Flier JS, Spiegelman BM. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. *J Biol Chem* 1992; **267**: 9210-9213 [PMID: 1374388]
- 50 **Xu Y**, Ma M, Ippolito GC, Schroeder HW, Carroll MC, Volanakis JE. Complement activation in factor D-deficient mice. *Proc Natl Acad Sci USA* 2001; **98**: 14577-14582 [PMID: 11724962 DOI: 10.1073/pnas.261428398]
- 51 **Stahl GL**, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H. Role for the alternative complement pathway in ischemia/reperfusion injury. *Am J Pathol* 2003; **162**: 449-455 [PMID: 12547703 DOI: 10.1016/S0002-9440(10)63839-4]
- 52 **Dahlke K**, Wrann CD, Sommerfeld O, Sossdorf M, Recknagel P, Sachse S, Winter SW, Klos A, Stahl GL, Ma YX, Claus RA, Reinhart K, Bauer M, Riedemann NC. Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis. *J Immunol* 2011; **186**: 3066-3075 [PMID: 21263075 DOI: 10.4049/jimmunol.1002741]
- 53 **Lo JC**, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, Kelly ME, Chatterjee Bhowmick D, Murano I, Cohen P, Banks AS, Khandekar MJ, Dietrich A, Flier JS, Cinti S, Blüher M, Danial NN, Berggren PO, Spiegelman BM. Adipsin is an adipokine that improves β cell function in diabetes. *Cell* 2014; **158**: 41-53 [PMID: 24995977 DOI: 10.1016/j.cell.2014.06.005]
- 54 **Ronti T**, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. *Clin Endocrinol (Oxf)* 2006; **64**: 355-365 [PMID: 16584505 DOI: 10.1111/j.1365-2265.2006.02474.x]
- 55 **Germinario R**, Sniderman AD, Manuel S, Lefebvre SP, Baldo A, Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. *Metabolism* 1993; **42**: 574-580 [PMID: 8492712 DOI: 10.1016/0026-0495(93)90215-A]
- 56 **Baas T**. Adipsin meet B cells. *T SciBX* 2014; **7**: 30 [DOI: 10.1038/scibx.2014.883]
- 57 **Zhang JH**, Wang JP, Wang HJ. [Clinical study on effect of total panax notoginseng saponins on immune related inner environment imbalance in rheumatoid arthritis patients]. *Zhongguo Zhongxiyi Jiehe Zazhi* 2007; **27**: 589-592 [PMID: 17717913]
- 58 **Di Raimo T**, Azzara G, Corsi M, Cipollone D, Lo Vasco VR, Businaro R. Adipokines and their involvement as a target of new drugs. *J Pharmacovigilance* 2015; **3**: 2-10 [DOI: 10.4172/2329-6887.1000166]
- 59 **Klötting N**, Kovacs P, Kern M, Heiker JT, Fasshauer M, Schön MR, Stumvoll M, Beck-Sickinger AG, Blüher M. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. *Diabetologia* 2011; **54**: 1819-1823 [PMID: 21465327 DOI: 10.1007/s00125-011-2137-1]
- 60 **Romacho T**, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. *Mediators Inflamm* 2013; **2013**: 946427 [PMID: 23843684 DOI: 10.1155/2013/946427]
- 61 **Brown JE**, Onyango DJ, Ramanjaneya M, Conner AC, Patel ST, Dunmore SJ, Randeve HS. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. *J Mol Endocrinol* 2010; **44**: 171-178 [PMID: 19906834 DOI: 10.1677/JME-09-0071]
- 62 **Gouranton E**, Romier B, Marcotorchino J, Tourniaire F, Astier J, Peiretti F, Landrier JF. Visfatin is involved in TNF α -mediated insulin resistance via an NAD(+)/Sirt1/PTP1B pathway in 3T3-L1 adipocytes. *Adipocyte* 2014; **3**: 180-189 [PMID: 25068084 DOI: 10.4161/adip.28729]
- 63 **Manning BD**, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007; **129**: 1261-1274 [PMID: 17604717 DOI: 10.1016/j.cell.2007.06.009]
- 64 **Zhou H**, Yang X, Wang NL, Zhang YO, Cai GP. Macrostemonoside A promotes visfatin expression in 3T3-L1 cells. *Biol Pharm Bull* 2007; **30**: 279-283 [PMID: 17268065 DOI: 10.1248/bpb.30.279]
- 65 **Sobolewska D**, Michalska K, Podolak I, Grabowska K. Steroidal saponins from the genus *Allium*. *Phytochem Rev* 2016; **15**: 1-35 [PMID: 26893594 DOI: 10.1007/s11101-014-9381-1]
- 66 **Turer AT**, Scherer PE. Adiponectin: mechanistic insights and clinical implications. *Diabetologia* 2012; **55**: 2319-2326 [PMID: 22688349 DOI: 10.1007/s00125-012-2598-x]
- 67 **Matsuzawa Y**, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2004; **24**: 29-33 [PMID: 14551151 DOI: 10.1161/01.ATV.0000099786.99623.EF]
- 68 **Fasshauer M**, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2002; **290**: 1084-1089 [PMID: 11798186 DOI: 10.1006/bbrc.2001.6307]
- 69 **Hurt RT**, Edakkanambeth Varayil J, Ebbert JO. New pharmacological treatments for the management of obesity. *Curr Gastroenterol Rep* 2014; **16**: 394 [PMID: 24828101 DOI: 10.1007/s11894-014-0394-0]
- 70 **Dray C**, Knauf C, Daviaud D, Waget A, Boucher J, Buléon M, Cani PD, Attané C, Guigné C, Carpené C, Burcelin R, Castan-Laurell I, Valet P. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. *Cell Metab* 2008; **8**: 437-445 [PMID: 18444444 DOI: 10.1016/j.cmet.2008.05.005]

- 19046574 DOI: 10.1016/j.cmet.2008.10.003]
- 71 **Bertrand C**, Valet P, Castan-Laurell I. Apelin and energy metabolism. *Front Physiol* 2015; **6**: 115 [PMID: 25914650 DOI: 10.3389/fphys.2015.00115]
 - 72 **Yue P**, Jin H, Aillaud M, Deng AC, Azuma J, Asagami T, Kundu RK, Reaven GM, Quertermous T, Tsao PS. Apelin is necessary for the maintenance of insulin sensitivity. *Am J Physiol Endocrinol Metab* 2010; **298**: E59-E67 [PMID: 19861585 DOI: 10.1152/ajpendo.00385.2009]
 - 73 **Xiu-Juan W**, Yi-Nan W, Hong J, Qing M, Rong W. Effects of astragalus on expression of Apelin /APJ in human umbilical vein endothelial cells exposed to high glucose. *J Shandong Uni (Health Sciences)* 2010; **4**: 10-14
 - 74 **Ragheb R**, Medhat AM. Mechanisms of fatty acid-induced insulin resistance in muscle and liver. *J Diabetes Metab* 2011; **2**: 127 [DOI: 10.4172/2155-6156.1000127]

P- Reviewer: Johansen OE, Shan YF, Su CC **S- Editor:** Ji FF
L- Editor: A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

